Nakajima, Atsushi

Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., et al. (2022) · Nature Reviews Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects

Cited by 757

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis

Mózes, F. E., Lee, J. A., Selvaraj, E. A., Jayaswal, A. N. A., Trauner, M., Boursier, J., Fournier, C., Staufer, K., Stauber, R. E., Bugianesi, E., et al. (2022) · Gut

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 556

Hyperresponsivity to Low-Dose Endotoxin during Progression to Nonalcoholic Steatohepatitis Is Regulated by Leptin-Mediated Signaling

Imajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 341

High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH

Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 294

Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease

Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., et al. (2024) · JAMA

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 250

Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis # †

Fujita, K., Nozaki, Y., Wada, K., Yoneda, M., Fujimoto, Y., Fujitake, M., Endo, H., Takahashi, H., Inamori, M., Kobayashi, N., et al. (2009) · Hepatology

Liver Disease Diagnosis and TreatmentLipid metabolism and disorders

Cited by 244

Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis

Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology

Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation

Cited by 214

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Nakajima, A., Eguchi, Y., Yoneda, M., Imajo, K., Tamaki, N., Suganami, H., Nojima, T., Tanigawa, R., Iizuka, M., Iida, Y., et al. (2021) · Alimentary Pharmacology & Therapeutics

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated Receptors

Cited by 213

Metformin suppresses intestinal polyp growth in Apc Min/+ mice

Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakajima, N., Nagashima, Y., Wada, K., Nakagama, H., et al. (2008) · Cancer Science

Metabolism, Diabetes, and CancerPI3K/AKT/mTOR signaling in cancer

Cited by 185

Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial

Nakajima, A., Seki, M., Taniguchi, S., Ohta, A., Gillberg, P.-G., Mattsson, J. P., & Camilleri, M. (2018) · The Lancet Gastroenterology & Hepatology

Gastrointestinal motility and disordersPelvic floor disorders treatments

Cited by 169

Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD

Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2022) · Hepatology Communications

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 153

Clinical utility of magnetic resonance imaging biomarkers for identifying nonalcoholic steatohepatitis patients at high risk of progression: a multicenter pooled data and meta-analysis

Andersson, A., Kelly, M., Imajo, K., Nakajima, A., Fallowfield, J. A., Hirschfield, G., Pavlides, M., Sanyal, A. J., Noureddin, M., Banerjee, R., et al. (2022) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentAdvanced MRI Techniques and Applications

Cited by 148

Direct comparison of US and MR elastography for staging liver fibrosis in patients with nonalcoholic fatty liver disease

Imajo, K., Honda, Y., Kobayashi, T., Nagai, K., Ozaki, A., Iwaki, M., Kessoku, T., Ogawa, Y., Takahashi, H., Saigusa, Y., et al. (2022) · Clinical Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography

Cited by 140

Non‐alcoholic fatty liver disease comorbid with major depressive disorder: the pathological features and poor therapeutic efficacy

Tomeno, W., Kawashima, K., Yoneda, M., Saito, S., Ogawa, Y., Honda, Y., Kessoku, T., Imajo, K., Mawatari, H., Fujita, K., et al. (2015) · Journal of Gastroenterology and Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 98

Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial

Fukudo, S., Endo, Y., Hongo, M., Nakajima, A., Abe, T., Kobayashi, H., Nakata, T., Nakajima, T., Sameshima, K., Kaku, K., et al. (2018) · The Lancet Gastroenterology & Hepatology

Gastrointestinal motility and disordersPelvic floor disorders treatments

Cited by 50

Global Prevalence, Clinical Characteristics, Surveillance, Treatment Allocation, and Outcomes of Alcohol-Associated Hepatocellular Carcinoma

Zeng, R. W., Ong, C. E. Y., Ong, E. Y. H., Chung, C. H., Lim, W. H., Xiao, J., Danpanichkul, P., Law, J. H., Syn, N., Chee, D., et al. (2024) · Clinical Gastroenterology and Hepatology

Hepatocellular Carcinoma Treatment and PrognosisAlcohol Consumption and Health Effects

Cited by 47

Efficacy, long‐term safety, and impact on quality of life of elobixibat in more severe constipation: post hoc analyses of two phase 3 trials in Japan

Nakajima, A., Taniguchi, S., Kurosu, S., Gillberg, P., Mattsson, J. P., & Camilleri, M. (2019) · Neurogastroenterology & Motility

Gastrointestinal motility and disordersPelvic floor disorders treatments

Cited by 33

Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD

Takahashi, H., Kessoku, T., Kawanaka, M., Nonaka, M., Hyogo, H., Fujii, H., Nakajima, T., Imajo, K., Tanaka, K., Kubotsu, Y., et al. (2025) · Diabetes mellitus

Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management

Cited by 1